Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 477,010 | 1,710,751 | 1,541,048 | 1,008,680 | 246,199 |
| Marketable Securities | 18,300 | 25,721 | 647,872 | 1,053,263 | 94,455 |
| Receivables | 36,647 | 36,597 | 68,309 | 39,166 | 38,766 |
| Other current assets | 742,236 | 781,839 | 620,982 | 595,789 | 452,652 |
| TOTAL | $1,274,193 | $2,554,908 | $2,878,211 | $2,696,898 | $832,072 |
| Non-Current Assets | |||||
| PPE Net | 14,088,660 | 13,493,110 | 13,718,250 | 12,368,080 | 10,842,050 |
| Investments And Advances | 1,012,481 | 735,823 | 909,594 | 916,641 | 678,412 |
| Intangibles | 0 | 0 | 5,670 | 28,666 | 51,724 |
| Other Non-Current Assets | 6,519 | 29,627 | 4,136 | 10,003 | 45,634 |
| TOTAL | $15,107,660 | $14,258,560 | $14,637,650 | $13,323,390 | $11,617,820 |
| Total Assets | $16,381,850 | $16,813,470 | $17,515,870 | $16,020,290 | $12,449,890 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 997,512 | N/A | N/A | 291,199 |
| Accounts payable and accrued liabilities | 98,320 | 102,709 | 113,554 | 155,741 | 42,218 |
| Accrued Expenses | 51,682 | 54,162 | 57,696 | 152,146 | N/A |
| Other current liabilities | 11,375 | 12,400 | N/A | N/A | N/A |
| TOTAL | $161,377 | $1,166,783 | $171,250 | $307,887 | $333,417 |
| Non-Current Liabilities | |||||
| Long Term Debt | 6,135,285 | 6,118,810 | 7,096,070 | 5,816,584 | 5,975,040 |
| Other Non-Current Liabilities | -564,354 | -184,732 | -621,473 | -726,914 | -112,884 |
| TOTAL | $6,136,185 | $6,121,310 | $7,096,070 | $5,816,584 | $5,975,040 |
| Total Liabilities | $6,297,562 | $7,288,093 | $7,267,320 | $6,124,471 | $6,308,457 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 597,435 | 607,224 | 607,176 | 607,111 | N/A |
| Common Shares | 108 | 107 | 106 | 102 | N/A |
| Retained earnings | 2,517,583 | 1,964,689 | 2,255,179 | 1,920,635 | 2,825,212 |
| Other shareholders' equity | 3,558,164 | 3,897,417 | 4,488,722 | 5,111,114 | 3,320,226 |
| TOTAL | $10,084,290 | $9,525,373 | $10,248,540 | $9,895,815 | $6,141,438 |
| Total Liabilities And Equity | $16,381,852 | $16,813,466 | $17,515,860 | $16,020,286 | $12,449,895 |